ResearcherTrinity Health Oakland HospitalNo recent work listed

Jasmeet Kaur

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4507-8157; OpenAlex author ID A5059080733. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 2 papers

Papers 2

Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. Co-author DOI 10.1080/14728214.2021.1905795 ↗
Immunotherapeutic approach for advanced pancreatic adenocarcinoma. Co-author DOI 10.2217/imt-2020-0344 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Thomas Enzler · 1 shared paper, 2021 · strength 0.19
- Paper Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. DOI 10.1080/14728214.2021.1905795 ↗
Vaibhav Sahai · 1 shared paper, 2021 · strength 0.19
- Paper Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. DOI 10.1080/14728214.2021.1905795 ↗
Rafiullah Khan · 1 shared paper, 2021 · strength 0.16
- Paper Immunotherapeutic approach for advanced pancreatic adenocarcinoma. DOI 10.2217/imt-2020-0344 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.